A detailed history of Assetmark, Inc transactions in Ligand Pharmaceuticals Inc stock. As of the latest transaction made, Assetmark, Inc holds 26 shares of LGND stock, worth $2,531. This represents 0.0% of its overall portfolio holdings.

Number of Shares
26
Previous 26 -0.0%
Holding current value
$2,531
Previous $1,000 100.0%
% of portfolio
0.0%
Previous 0.0%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 06, 2024

BUY
$68.64 - $89.2 $1,784 - $2,319
26 New
26 $1,000
Q1 2022

May 13, 2022

SELL
$94.99 - $151.56 $1,899 - $3,031
-20 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$127.69 - $165.85 $2,553 - $3,317
20 New
20 $3,000
Q4 2020

Feb 10, 2021

SELL
$80.55 - $106.05 $483 - $636
-6 Closed
0 $0
Q2 2020

Aug 11, 2020

SELL
$68.28 - $123.65 $158,341 - $286,744
-2,319 Reduced 99.74%
6 $1,000
Q1 2020

May 12, 2020

SELL
$63.37 - $107.88 $12,420 - $21,144
-196 Reduced 7.77%
2,325 $169,000
Q4 2019

Feb 11, 2020

BUY
$96.94 - $113.59 $213,655 - $250,352
2,204 Added 695.27%
2,521 $263,000
Q3 2019

Nov 13, 2019

BUY
$86.25 - $120.16 $26,823 - $37,369
311 Added 5183.33%
317 $32,000
Q1 2018

May 16, 2018

SELL
$138.63 - $182.62 $145,561 - $191,751
-1,050 Reduced 99.43%
6 $1,000
Q4 2017

Feb 13, 2018

BUY
$128.36 - $147.04 $104,485 - $119,690
814 Added 336.36%
1,056 $145,000
Q3 2017

Nov 08, 2017

SELL
$120.91 - $137.94 $1,692 - $1,931
-14 Reduced 5.47%
242 $33,000
Q2 2017

Aug 15, 2017

SELL
N/A
-1 Reduced 0.39%
256 $31,000
Q1 2017

Sep 15, 2017

SELL
N/A
-30 Reduced 10.45%
257 $27,000
Q4 2016

Sep 15, 2017

BUY
N/A
3 Added 1.06%
287 $29,000
Q3 2016

Sep 15, 2017

SELL
N/A
-32 Reduced 10.13%
284 $29,000
Q2 2016

Sep 15, 2017

BUY
N/A
178 Added 128.99%
316 $38,000
Q1 2016

Sep 15, 2017

BUY
N/A
119 Added 626.32%
138 $15,000
Q4 2015

Sep 15, 2017

BUY
N/A
19
19 $2,000

Others Institutions Holding LGND

About LIGAND PHARMACEUTICALS INC


  • Ticker LGND
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 16,882,800
  • Market Cap $1.64B
  • Description
  • Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...
More about LGND
Track This Portfolio

Track Assetmark, Inc Portfolio

Follow Assetmark, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Assetmark, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Assetmark, Inc with notifications on news.